The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Könnecke, Helen ^a   Bechmann, Ingo ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ARTICLE; BLOOD BRAIN BARRIER; CANCER INHIBITION; CELL MIGRATION; ENZYME INDUCTION; GLIOBLASTOMA; HUMAN; IMMUNOCOMPETENT CELL; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BRAIN TUMOR; GLIOMA; IMMUNOLOGY; INFLAMMATION; METABOLISM; REVIEW;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; GLIOMA; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; MICROGLIA;

EID: 84884218376     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/914104     Document Type: Article

References (203)

1. Rosenberg G. A., Matrix metalloproteinases in neuroinflammation. GLIA 2002 39 3 279 291
2. Tanaka R., Iwasaki Y., Koprowski H., Ultrastructural studies of perivascular cuffing cells in multiple sclerosis brain. American Journal of Pathology 1975 81 3 467 478 2-s2.0-0016679093
3. Bechmann I., Galea I., Perry V. H., What is the blood-brain barrier (not)? Trends in Immunology 2007 28 1 5 11 2-s2.0-33845727067 10.1016/j.it.2006.11.007
4. Uccelli A., Aloisi F., Pistoia V., Unveiling the enigma of the CNS as a B-cell fostering environment. Trends in Immunology 2005 26 5 254 259 2-s2.0-24144496803 10.1016/j.it.2005.02.009
5. Hickey W. F., Basic principles of immunological surveillance of the normal central nervous system. GLIA 2001 36 2 118 124 2-s2.0-0035155254 10.1002/glia.1101
6. Goetzl E. J., Banda M. J., Leppert D., Matrix metalloproteinases in immunity. Journal of Immunology 1996 156 1 1 4 2-s2.0-0030028043
7. Madri J. A., Graesser D., Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. Developmental Immunology 2000 7 2-4 103 116 2-s2.0-0033768928
8. Leppert D., Waubant E., Galardy R., Bunnett N. W., Hauser S. L., T cell gelatinases madiate basement membrane transmigration in vitro. Journal of Immunology 1995 154 9 4379 4389 2-s2.0-0029041446
9. Xia M., Sreedharan S. P., Dazin P., Damsky C. H., Goetzl E. J., Integrin-dependent role of human T cell matrix metalloproteinase activity in chemotaxis through a model basement membrane. Journal of Cellular Biochemistry 1996 61 3 452 458
10. Graesser G., Integrins, proteinases, and EAE: Explaining a complex web of interactions. Laboratory Investigation 1998 78 12 1445
11. Laurie G. W., Leblond C. P., Martin G. R., Localization of type IV collagen, laminin, heparan sulfate proteoglycan, and fibronectin to the basal lamina of basement membranes. Journal of Cell Biology 1982 95 1 340 344 2-s2.0-0020358297
12. Sixt M., Engelhardt B., Pausch F., Hallmann R., Wendler O., Sorokin L. M., Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. Journal of Cell Biology 2001 153 5 933 945 2-s2.0-0035947768 10.1083/jcb.153.5.933
13. van den Steen P. E., Dubois B., Nelissen I., Rudd P. M., Dwek R. A., Opdenakker G., Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Critical Reviews in Biochemistry and Molecular Biology 2002 37 6 375 536 2-s2.0-0038059516 10.1080/10409230290771546
14. Tian M., Jacobson C., Gee S. H., Campbell K. P., Carbonetto S., Jucker M., Dystroglycan in the cerebellum is a laminin alpha 2-chain binding protein at the glial-vascular interface and is expressed in Purkinje cells. European Journal of Neuroscience 1996 8 12 2739 2747 10.1111/j.1460-9568.1996.tb01568.x
15. Zaccaria M. L., Di Tommaso F., Brancaccio A., Paggi P., Petrucci T. C., Dystroglycan distribution in adult mouse brain: a light and electron microscopy study. Neuroscience 2001 104 2 311 324 2-s2.0-0035837298 10.1016/S0306-4522(01) 00092-6
16. Agrawal S., Anderson P., Durbeej M., Van Rooijen N., Ivars F., Opdenakker G., Sorokin L. M., Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2006 203 4 1007 1016 2-s2.0-33645869560 10.1084/jem.20051342
17. Parks W. C., Wilson C. L., López-Boado Y. S., Matrix metalloproteinases as modulators of inflammation and innate immunity. Nature Reviews Immunology 2004 4 8 617 629 2-s2.0-3543134126
18. Visse R., Nagase H., Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation Research 2003 92 8 827 839
19. Woessner J. F. Jr., Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB Journal 1991 5 8 2145 2154 2-s2.0-0025847582
20. Sternlicht M. D., Werb Z., How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology 2001 17 463 516 2-s2.0-0035188727 10.1146/annurev.cellbio.17.1.463
21. Alexander C. M., Werb Z., Proteinases and extracellular matrix remodeling. Current Opinion in Cell Biology 1989 1 5 974 982 2-s2.0-0024840912 10.1016/0955-0674(89)90068-9
22. Matsumoto S. I., Kobayashi T., Katoh M., Saito S., Ikeda Y., Kobori M., Masuho Y., Watanabe T., Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. American Journal of Pathology 1998 153 1 109 119 2-s2.0-0031847419
23. Yong V. W., Power C., Forsyth P., Edwards D. R., Metalloproteinases in biology and pathology of the nervous system. Nature Reviews Neuroscience 2001 2 7 502 511 2-s2.0-0035405886 10.1038/35081571
24. Agrawal S. M., Lau L., Yong V. W., MMPs in the central nervous system: where the good guys go bad. Seminars in Cell and Developmental Biology 2008 19 1 42 51 2-s2.0-36849030749 10.1016/j.semcdb.2007.06.003
25. Rosenberg G. A., Dencoff J. E., McGuire P. G., Liotta L. A., Stetler-Stevenson W. G., Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Laboratory Investigation 1994 71 3 417 422 2-s2.0-0028136996
26. Yong V. W., Krekoski C. A., Forsyth P. A., Bell R., Edwards D. R., Matrix metalloproteinases and diseases of the CNS. Trends in Neurosciences 1998 21 2 75 80 2-s2.0-0031989284
27. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D. L., Quigley J. P., Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. Journal of Biological Chemistry 1999 274 19 13066 13076 2-s2.0-0033532205 10.1074/jbc.274.19.13066
28. Lorenzl S., Calingasan N., Yang L., Albers D. S., Shugama S., Gregorio J., Krell H. W., Chirichigno J., Joh T., Beal M. F., Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. NeuroMolecular Medicine 2004 5 2 119 131 2-s2.0-2342448576 10.1385/NMM:5:2:119
29. Yin K. J., Cirrito J. R., Yan P., Hu X., Xiao Q., Pan X., Bateman R., Song H., Hsu F. F., Turk J., Xu J., Hsu C. Y., Mills J. C., Holtzman D. M., Lee J. M., Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid- β peptide catabolism. Journal of Neuroscience 2006 26 43 10939 10948 2-s2.0-33751112725 10.1523/JNEUROSCI.2085-06.2006
30. Weaver A., Goncalves da Silva A., Nuttall R. K., Edwards D. R., Shapiro S. D., Rivest S., Yong V. W., An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. The FASEB Journal 2005 19 12 1668 1670
31. Yong V. W., Metalloproteinases: mediators of pathology and regeneration in the CNS. Nature Reviews Neuroscience 2005 6 12 931 944 2-s2.0-28644435880 10.1038/nrn1807
32. Woessner J. F. Jr., Quantification of matrix metalloproteinases in tissue samples. Methods in Enzymology 1995 248 510 528 2-s2.0-0029001584 10.1016/0076-6879(95)48033-1
33. Vos C. M. P., Gartner S., Ransohoff R. M., McArthur J. C., Wahl L., Sjulson L., Hunter E., Conant K., Matrix metalloprotease-9 release from monocytes increases as a function of differentiation: implications for neuroinflammation and neurodegeneration. Journal of Neuroimmunology 2000 109 2 221 227 2-s2.0-0034703293 10.1016/S0165-5728(00)00308-8
34. Hu J., van den Steen P. E., Sang Q. X. A., Opdenakker G., Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Reviews Drug Discovery 2007 6 6 480 498 2-s2.0-34447520043 10.1038/nrd2308
35. Page-McCaw A., Ewald A. J., Werb Z., Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews Molecular Cell Biology 2007 8 3 221 233 2-s2.0-33847195428 10.1038/nrm2125
36. Gearing A. J. H., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A. H., Drummond A. H., Galloway W. A., Gilbert R., Gordon J. L., Leber T. M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Wood L. M., Wooley K., Processing of tumour necrosis factor- α precursor by metalloproteinases. Nature 1994 370 6490 555 557 2-s2.0-0028485654 10.1038/370555a0
37. Chandler S., Miller K. M., Clements J. M., Lury J., Corkill D., Anthony D. C. C., Adams S. E., Gearing A. J. H., Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. Journal of Neuroimmunology 1997 72 2 155 161 2-s2.0-0031040486 10.1016/S0165-5728(96)00179-8
38. Block M. L., Zecca L., Hong J. S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 2007 8 1 57 69 2-s2.0-33845768784 10.1038/nrn2038
39. Kim S. U., de Vellis J., Microglia in health and disease. Journal of Neuroscience Research 2005 81 3 302 313 2-s2.0-25444495866 10.1002/jnr.20562
40. Streit W. J., Conde J. R., Fendrick S. E., Flanary B. E., Mariani C. L., Role of microglia in the central nervous system's immune response. Neurological Research 2005 27 7 685 691 2-s2.0-27244451954 10.1179/016164105X49463
41. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 38 8 1285 1291 2-s2.0-0023789193
42. Gao H. M., Liu B., Hong J. S., Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. Journal of Neuroscience 2003 23 15 6181 6187 2-s2.0-0038044029
43. Glezer I., Simard A. R., Rivest S., Neuroprotective role of the innate immune system by microglia. Neuroscience 2007 147 4 867 883 2-s2.0-34547127632 10.1016/j.neuroscience.2007.02.055
44. Simard A. R., Rivest S., Neuroprotective effects of resident microglia following acute brain injury. Journal of Comparative Neurology 2007 504 6 716 729 2-s2.0-37049028157 10.1002/cne.21469
45. Kim Y. S., Joh T. H., Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Experimental and Molecular Medicine 2006 38 4 333 347 2-s2.0-33748447845
46. Kim Y. S., Choi D. H., Block M. L., Lorenzl S., Yang L., Kim Y. J., Sugama S., Cho B. P., Hwang O., Browne S. E., Kim S. Y., Hong J. S., Beal M. F., Joh T. H., A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. The FASEB Journal 2007 21 1 179 187 10.1096/fj.06-5865com
47. Wahl L. M., Lampel L. L., Regulation of human peripheral blood monocyte collagenase by prostaglandins and anti-inflammatory drugs. Cellular Immunology 1987 105 2 411 422 2-s2.0-0023187092
48. Lu Y., Wahl L. M., Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF- B activity in lipopolysaccharide-activated human primary monocytes. Journal of Immunology 2005 175 8 5423 5429 2-s2.0-26844522332
49. Liuzzi G. M., Latronico T., Fasano A., Carlone G., Riccio P., Interferon-beta inhibits the expression of metallo proteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Multiple Sclerosis 2004 10 3 290 297
50. Nuttall R. K., Silva C., Hader W., Bar-Or A., Patel K. D., Edwards D. R., Yong V. W., Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. GLIA 2007 55 5 516 526 2-s2.0-33847723000 10.1002/glia.20478
51. Webster N. L., Crowe S. M., Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. Journal of Leukocyte Biology 2006 80 5 1052 1066 10.1189/jlb.0306152
52. Mignatti P., Rifkin D. B., Biology and biochemistry of proteinases in tumor invasion. Physiological Reviews 1993 73 1 161 195 2-s2.0-0027535914
53. Backstrom J. R., Tokes Z. A., The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. Journal of Neurochemistry 1995 64 3 1312 1318 2-s2.0-0028853330
54. Backstrom J. R., Lim G. P., Cullen M. J., Tökés Z. A., Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid- β peptide (1-40). Journal of Neuroscience 1996 16 24 7910 7919 2-s2.0-0029852887
55. Roher A. E., Kasunic T. C., Woods A. S., Cotter R. J., Ball M. J., Fridman R., Proteolysis of A β peptide from Alzheimer disease brain by gelatinase A. Biochemical and Biophysical Research Communications 1994 205 3 1755 1761 2-s2.0-0028670204 10.1006/bbrc.1994.2872
56. Proost P., Van Damme J., Opdenakker G., Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochemical and Biophysical Research Communications 1993 192 3 1175 1181 2-s2.0-0027169231 10.1006/bbrc.1993.1540
57. Gijbels K., Proost P., Masure S., Carton H., Billiau A., Opdenakker G., Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. Journal of Neuroscience Research 1993 36 4 432 440 2-s2.0-0027368518 10.1002/jnr.490360409
58. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E., Matrix metalloproteinases degrade myelin basic protein. Neuroscience Letters 1995 201 3 223 226 2-s2.0-0029586166 10.1016/0304-3940(95)12173-0
59. Opdenakker G., van den Steen P. E., van Damme J., Gelatinase B: a tuner and amplifier of immune functions. Trends in Immunology 2001 22 10 571 579 2-s2.0-0035471778 10.1016/S1471-4906(01)02023-3
60. Lukes A., Mun-Bryce S., Lukes M., Rosenberg G. A., Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Molecular Neurobiology 1999 19 3 267 284 2-s2.0-0032821995
61. Rosenberg G. A., Dencoff J. E., Correa N. Jr., Reiners M., Ford C. C., Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996 46 6 1626 1632 2-s2.0-0029889674
62. Rosenberg G. A., Estrada E. Y., Dencoff J. E., Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998 29 10 2189 2195 2-s2.0-0031693557
63. Anthony D. C., Miller K. M., Fearn S., Townsend M. J., Opdenakker G., Wells G. M. A., Clements J. M., Chandler S., Gearing A. J. H., Perry V. H., Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. Journal of Neuroimmunology 1998 87 1-2 62 72 2-s2.0-0032126878 10.1016/S0165-5728(98)00046-0
64. Mun-Bryce S., Rosenberg G. A., Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. American Journal of Physiology 1998 274 5 R1203 R1211 2-s2.0-0031831764
65. Asahi M., Asahi K., Jung J. C., del Zoppo G. J., Fini M. E., Lo E. H., Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-4. Journal of Cerebral Blood Flow & Metabolism 2000 20 12 1681 199
66. Romanic A. M., White R. F., Arleth A. J., Ohlstein E. H., Barone F. C., Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998 29 5 1020 1030 2-s2.0-0031959973
67. Kermode A. G., Thompson A. J., Tofts P., MacManus D. G., Kendall B. E., Kingsley D. P. E., Moseley I. F., Rudge P., McDonald W. I., Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenic and clinical implications. Brain 1990 113 part 5 1477 1489 2-s2.0-0024990661
68. Kwon E. E., Prineas J. W., Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. Journal of Neuropathology and Experimental Neurology 1994 53 6 625 636 2-s2.0-0028089844
69. Rosenberg G. A., Matrix metalloproteinases in brain injury. Journal of Neurotrauma 1995 12 5 833 842 2-s2.0-0028825270
70. Romanic A. M., Madri J. A., Extracellular matrix-degrading proteinases in the nervous system. Brain Pathology 1994 4 2 145 156 2-s2.0-0028255910
71. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hämmerling G., Opdenakker G., Arnold B., Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. Journal of Clinical Investigation 1999 104 11 1507 1515 10.1172/JCI6886
72. Kieseier B. C., Kiefer R., Clements J. M., Miller K., Wells G. M. A., Schweitzer T., Gearing A. J. H., Hartung H. P., Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998 121 part 1 159 166 2-s2.0-0031963338 10.1093/brain/121.1.159
73. Lindberg R. L., de Groot C. J., Montagne L., Freitag P., van der Valk P., Kappos L., Leppert D., The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 2001 124 9 1743 1753 10.1093/brain/124.9.1743
74. Maeda A., Sobel R. A., Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. Journal of Neuropathology and Experimental Neurology 1996 55 3 300 309 2-s2.0-0029867128
75. Cossins J. A., Clements J. M., Ford J., Miller K. M., Pigott R., Vos W., Van Der Valk P., de Groot C. J. A., Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathologica 1997 94 6 590 598 2-s2.0-0030806651 10.1007/s004010050754
76. Diaz-Sanchez M., Williams K., DeLuca G. C., Esiri M. M., Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathologica 2006 111 4 289 299 2-s2.0-33645764948 10.1007/s00401-006-0045-0
77. Newman T. A., Woolley S. T., Hughes P. M., Sibson N. R., Anthony D. C., Perry V. H., T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 2001 124 11 2203 2214 2-s2.0-0035170589
78. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Brück W., Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000 123 part 6 1174 1183 2-s2.0-0034026912
79. DeLuca G. C., Ebers G. C., Esiri M. M., Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004 127 5 1009 1018 2-s2.0-2442555263 10.1093/brain/awh118
80. Trapp B. D., Peterson J., Ransohoff R. M., Rudick R., Mörk S., Bö L., Axonal transection in the lesions of multiple sclerosis. New England Journal of Medicine 1998 338 5 278 285 2-s2.0-0032576752 10.1056/ NEJM199801293380502
81. Kuhlmann T., Lingfeld G., Bitsch A., Schuchardt J., Brück W., Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002 125 10 2202 2212 2-s2.0-0036788406
82. Bitsch A., Da Costa C., Bunkowski S., Weber F., Rieckmann P., Brück W., Identification of macrophage populations expressing tumor necrosis factor- α mRNA in acute multiple sclerosis. Acta Neuropathologica 1998 95 4 373 377 2-s2.0-0031952236 10.1007/s004010050813
83. Koeberle P. D., Ball A. K., Nitric oxide synthase inhibition delays axonal degeneration and promotes the survival of axotomized retinal ganglion cells. Experimental Neurology 1999 158 2 366 381 2-s2.0-0032816287 10.1006/exnr.1999.7113
84. Cuzner M. L., Gveric D., Strand C., Loughlin A. J., Paemen L., Opdenakker G., Newcombe J., The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. Journal of Neuropathology and Experimental Neurology 1996 55 12 1194 1204 2-s2.0-0029907622
85. Liuzzi G. M., Trojano M., Fanelli M., Avolio C., Fasano A., Livrea P., Riccio P., Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Multiple Sclerosis 2002 8 3 222 228
86. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K. M., Hauser S. L., Kappos L., Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998 121 part 12 2327 2334 2-s2.0-0031798063
87. Gijbels K., Galardy R. E., Steinman L., Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. Journal of Clinical Investigation 1994 94 6 2177 2182 2-s2.0-0027944171
88. Hewson A. K., Smith T., Leonard J. P., Cuzner M. L., Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflammation Research 1995 44 8 345 349 2-s2.0-0029046464 10.1007/BF01796266
89. Clements J. M., Cossins J. A., Wells G. M., Corkill D. J., Helfrich K., Wood L. M., Pigott R., Stabler G., Ward G. A., Gearing A. J., Miller K. M., Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-a inhibitor. Journal of Neuroimmunology 1997 74 1 85 94
90. Toft-Hansen H., Buist R., Sun X. J., Schellenberg A., Peeling J., Owens T., Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system. Journal of Immunology 2006 177 10 7242 7249 2-s2.0-33750837704
91. Corcoran M. L., Stetler-Stevenson W. G., Brown P. D., Wahl L. M., Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. Journal of Biological Chemistry 1992 267 1 515 519 2-s2.0-0026515544
92. Arthur F. E., Shivers R. R., Bowman P. D., Astrocyte-mediated induction of tight junctions in brain capillary endothelium: an efficient in vitro model. Brain Research 1987 433 1 155 159 2-s2.0-0023441907
93. Malik N., Greenfield B. W., Wahl A. F., Kiener P. A., Activation of human monocytes through CD40 induces matrix metalloproteinases. Journal of Immunology 1996 156 10 3952 3960 2-s2.0-0029983775
94. Zhou H., Bernhard E. J., Fox F. E., Billings P. C., Induction of metalloproteinase activity in human T-lymphocytes. Biochimica et Biophysica Acta 1993 1177 2 174 178 2-s2.0-0027263844 10.1016/0167-4889(93)90037-P
95. Harkness K. A. C., Adamson P., Sussman J. D., Davies-Jones G. A. B., Greenwood J., Woodroofe M. N., Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 2000 123 part 4 698 709 2-s2.0-0034121588
96. Owens T., Renno T., Taupin V., Krakowski M., Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunology Today 1994 15 12 566 571 2-s2.0-0028029946 10.1016/0167-5699(94)90218-6
97. Opdenakker G., Masure S., Grillet B., van Damme J., Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine and Cytokine Research 1991 10 4 317 324 2-s2.0-0025883322
98. Opdenakker G., Masure S., Proost P., Billiau A., van Damme J., Natural human monocyte gelatinase and its inhibitor. FEBS Letters 1991 284 1 73 78 2-s2.0-0025828350 10.1016/0014-5793(91)80765-U
99. Johnatty R. N., Taub D. D., Reeder S. P., Turcovski-Corrales S. M., Cottam D. W., Stephenson T. J., Rees R. C., Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. Journal of Immunology 1997 158 5 2327 2333 2-s2.0-0031091749
100. Leppert D., Hauser S. L., Kishiyama J. L., An S., Zeng L., Goetzl E. J., Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB Journal 1995 9 14 1473 1481 2-s2.0-0028860849
101. Schrijver I. A., Melief M. J., Markusse H. M., van Aelst I., Opdenakker G., Hazenberg M. P., Laman J. D., Peptidoglycan from sterile human spleen induces T-cell proliferation and inflammatory mediators in rheumatoid arthritis patients and healthy subjects. Rheumatology 2001 40 4 438 446 10.1093/rheumatology/40.4.438
102. Gottschall P. E., Yu X., Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. Journal of Neurochemistry 1995 64 4 1513 1520 2-s2.0-0028934085
103. Gottschall P. E., Yu X., Bing B., Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. Journal of Neuroscience Research 1995 42 3 335 342 2-s2.0-0028834682 10.1002/jnr.490420307
104. Liuzzi G. M., Latronico T., Fasano A., Carlone G., Riccio P., Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Multiple Sclerosis 2004 10 3 290 297 2-s2.0-3042694846 10.1191/ 1352458504ms1016oa
105. Ma Z., Qin H., Benveniste E. N., Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN- γ and IFN- β: critical role of STAT-1 α Journal of Immunology 2001 167 9 5150 5159 2-s2.0-0035500287
106. Sancéau J., Boyd D. D., Seiki M., Bauvois B., Interferons inhibit tumor necrosis factor- α -mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF- B. Journal of Biological Chemistry 2002 277 38 35766 35775 2-s2.0-0037144415 10.1074/jbc.M202959200
107. Cuzner M. L., Opdenakker G., Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. Journal of Neuroimmunology 1999 94 1-2 1 14 2-s2.0-0033081796 10.1016/S0165-5728(98)00241-0
108. Stuve Dooley NP O., Dooley N. P., Uhm J. H., Antel J. P., Francis G. S., Williams G., Yong V. W., Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Annals of Neurology 1996 40 6 853 863 10.1002/ana.410400607
109. Bartholomé E. J., van Aelst I., Koyen E., Kiss R., Willems F., Goldman M., Opdenakker G., Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. Journal of Interferon & Cytokine Research 2001 21 7 495 501 10.1089/10799900152434367.
110. Trojano M., Avolio C., Liuzzi G. M., Ruggieri M., Defazio G., Liguori M., Santacroce M. P., Paolicelli D., Giuliani F., Riccio P., Livrea P., Changes of serum sICAM-1 and MMP-9 induced by rIFN β -1b treatment in relapsing-remitting MS. Neurology 1999 53 7 1402 1408 2-s2.0-0032716573
111. Ozenci Kouwenhoven M V., Teleshova N., Pashenkov M., Fredrikson S., Link H., Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. Journal of Neuroimmunology 2000 108 1 236 243
112. Shapiro S., Shoenfeld Y., Gilburd B., Sobel E., Lahat N., Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002 95 9 2032 2037 2-s2.0-0036840967 10.1002/cncr.10905
113. Vaillant C., Didier-Bazès M., Hutter A., Belin M. F., Thomasset N., Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. Journal of Neuroscience 1999 19 12 4994 5004 2-s2.0-0033564779
114. Soler R. C., Gui Y. H., Linask K. K., Muschel R. J., MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. Developmental Brain Research 1995 88 1 37 52 2-s2.0-0029113115 10.1016/0165-3806(95)00079-S
115. Uhm J. H., Dooley N. P., Oh L. Y., Yong V. W., Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 1998 22 1 53 63
116. Oh L. Y. S., Larsen P. H., Krekoski C. A., Edwards D. R., Donovan F., Werb Z., Yong V. W., Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligoclendrocytes. Journal of Neuroscience 1999 19 19 8464 8475 2-s2.0-0033215979
117. Yu F., Kamada H., Niizuma K., Endo H., Chan P. H., Induction of MMP-9 expression and endothelial injury by oxidative stress after spinal cord injury. Journal of Neurotrauma 2008 25 3 184 195 2-s2.0-40949153084 10.1089/neu.2007. 0438
118. Buss Pech K A., Kakulas B. A., Martin D., Schoenen J., Noth J., Brook G. A., Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury. BMC Neurology 2007 7 article 17 10.1186/1471-2377-7-17
119. Larsen P. H., Wells J. E., Stallcup W. B., Opdenakker G., Yong V. W., Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. Journal of Neuroscience 2003 23 35 11127 11135 2-s2.0-0346749451
120. Larsen P. H., Yong V. W., The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation. Journal of Neuroscience 2004 24 35 7597 7603 2-s2.0-4444262381 10.1523/JNEUROSCI.2092-04.2004
121. Larsen P. H., DaSilva A. G., Conant K., Yong V. W., Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. Journal of Neuroscience 2006 26 8 2207 2214 2-s2.0-33645643179 10.1523/JNEUROSCI.1880-05.2006
122. Hsu J. Y. C., McKeon R., Goussev S., Werb Z., Lee J. U., Trivedi A., Noble-Haeusslein L. J., Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. Journal of Neuroscience 2006 26 39 9841 9850 2-s2.0-33749174156 10.1523/JNEUROSCI.1993-06. 2006
123. Haorah J., Ramirez S. H., Schall K., Smith D., Pandya R., Persidsky Y., Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. Journal of Neurochemistry 2007 101 2 566 576 2-s2.0-34047114464 10.1111/j.1471-4159.2006.04393.x
124. Luckow B., Joergensen J., Chilla S., Li J. P., Henger A., Kiss E., Wieczorek G., Roth L., Hartmann N., Hoffmann R., Kretzler M., Nelson P. J., Pérez de Lema G., Maier H., Wurst W., Balling R., Pfeffer K., Grne H. J., Schlndorff D., Zerwes H. G., Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice. European Journal of Immunology 2004 34 9 2568 2578 10.1002/eji.200324776
125. Woo M. S., Park J. S., Choi I. Y., Kimf W. K., Kim H. S., Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. Journal of Neurochemistry 2008 106 2 770 780 2-s2.0-51649102877 10.1111/j.1471-4159.2008.05430.x
126. Lassmann H., Zimprich F., Vass K., Hickey W. F., Microglial cells are a component of the perivascular glia limitans. Journal of Neuroscience Research 1991 28 2 236 243 2-s2.0-0026073369
127. Ethell I. M., Ethell D. W., Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. Journal of Neuroscience Research 2007 85 13 2813 2823 2-s2.0-34547957954 10.1002/jnr.21273
128. Nagy Bozdagi O V., Bozdagi O., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., Costa R. M., Silva A. J., Kaczmarek L., Huntley G. W., Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. Journal of Neuroscience 2006 26 7 1923 1934 10.1523/?JNEUROSCI.4359-05.2006
129. Holland E. C., Glioblastoma multiforme: the terminator. Proceedings of the National Academy of Sciences 2000 97 12 6242 6244 10.1073/pnas.97.12.6242
130. Takakura K., Abe H., Tanaka R., Effects of ACNU and radiotherapy on malignant glioma. Journal of Neurosurgery 1986 64 1 53 57 2-s2.0-0022630453
131. Shapiro W. R., Green S. B., Burger P. C., Selker R. G., vanGilder J. C., Robertson J. T., Mealey J. Jr., Ransohoff J., Mahaley M. S. Jr., A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. Journal of Neurosurgery 1992 76 5 772 781 2-s2.0-0026591763
132. Stupp R., Mason W. P., van den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005 352 10 987 996 2-s2.0-20044366163 10.1056/NEJMoa043330
133. van Meir E. G., Hadjipanayis C. G., Norden A. D., Shu H. K., Wen P. Y., Olson J. J., Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer Journal for Clinicians 2010 60 3 166 193 2-s2.0-77952555038 10.3322/caac.20069
134. Rio-hortega P., Sobre la fagocitosis en los tumores y en otros procesos patológicos/P. del Río-Hortega. Archivos de Cardiología y Hematología 1921 2 5 161 220
135. Graeber M. B., Scheithauer B. W., Kreutzberg G. W., Microglia in brain tumors. GLIA 2002 40 2 252 259 2-s2.0-0036850131 10.1002/glia.10147
136. Badie B., Schartner J., Role of microglia in glioma biology. Microscopy Research and Technique 2001 54 2 106 113 2-s2.0-0035879509 10.1002/jemt.1125
137. Ribot E., Bouzier-Sore A. K., Bouchaud V., Miraux S., Delville M. H., Franconi J. M., Voisin P., Microglia used as vehicles for both inducible thymidine kinase gene therapy and MRI contrast agents for glioma therapy. Cancer Gene Therapy 2007 14 8 724 737 2-s2.0-34447506370 10.1038/sj.cgt.7701060
138. Markovic D. S., Vinnakota K., Chirasani S., Synowitz M., Raguet H., Stock K., Sliwa M., Lehmann S., Klin R., van Rooijen N., Holmbeck K., Heppner F. L., Kiwit J., Matyash V., Lehnardt S., Kaminska B., Glass R., Kettenmann H., Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proceedings of the National Academy of Sciences of the United States of America 2009 106 30 12530 12535 10.1073/pnas.0804273106
139. Markovic D. S., Glass R., Synowitz M., van Rooijen N., Kettenmann H., Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. Journal of Neuropathology and Experimental Neurology 2005 64 9 754 762 2-s2.0-24644490056
140. Watters J. J., Schartner J. M., Badie B., Microglia function in brain tumors. Journal of Neuroscience Research 2005 81 3 447 455 2-s2.0-25444488717 10.1002/jnr.20485
141. Kerber M., Reiss Y., Wickersheim A., Jugold M., Kiessling F., Heil M., Tchaikovski V., Waltenberger J., Shibuya M., Plate K. H., Machein M. R., Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Research 2008 68 18 7342 7351 2-s2.0-54749092522 10.1158/0008-5472.CAN-07-6241
142. Zhai H., Heppner F. L., Tsirka S. E., Microglia/macrophages promote glioma progression. GLIA 2011 59 3 472 485 2-s2.0-78751700548 10.1002/glia.21117
143. Sliwa M., Markovic D., Gabrusiewicz K., Synowitz M., Glass R., Zawadzka M., Wesolowska A., Kettenmann H., Kaminska B., The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. Brain 2007 130 2 476 489 2-s2.0-33846567515 10.1093/brain/awl263
144. Grasbon-Frodl EMFA W. P., Klinkert W. E. F., Kreutzberg G. W., Graeber M. B., Jahrestagung der Neuroonkologischen Arbeitsgemeinschaft der Deutschen Gesellschaft fuer Neurochirurgie in Dresden 1998
145. Huettner C., Czub S., Kerkau S., Roggendorf W., Tonn J. C., Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Research 1997 17 5 A 3217 3224 2-s2.0-0030778631
146. Wagner S., Czub S., Greif M., Vince G. H., Süss N., Kerkau S., Rieckmann P., Roggendorf W., Roosen K., Tonn J. C., Microglial/macrophage expression of interleukin 10 in human glioblastomas. International Journal of Cancer 1999 82 1 12 16
147. Frei K., Siepl C., Groscurth P., Bodmer S., Schwerdel C., Fontana A., Antigen presentation and tumor cytotoxicity by interferon- γ -treated microglial cells. European Journal of Immunology 1987 17 9 1271 1278 2-s2.0-0023618311
148. Sutter A., Hekmat A., Luckenbach G. A., Antibody-mediated tumor cytotoxicity of microglia. Pathobiology 1991 59 4 254 258 2-s2.0-0025764920
149. Voisin P., Bouchaud V., Merle M., Diolez P., Duffy L., Flint K., Franconi J. M., Bouzier-Sore A. K., Microglia in close vicinity of glioma cells: correlation between phenotype and metabolic alterations. Frontiers in Neuroenergetics 2010 2 article 131 10.3389/fnene.2010.00131
150. Hussain S. F., Yang D., Suki D., Aldape K., Grimm E., Heimberger A. B., The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology 2006 8 3 261 279 2-s2.0-33748532939 10.1215/15228517-2006-008
151. Rao J. S., Molecular mechanisms of glioma invasiveness: the role of proteases. Nature Reviews Cancer 2003 3 489 501 10.1038/nrc1121
152. Hanisch U. K., Kettenmann H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nature Neuroscience 2007 10 11 1387 1394 2-s2.0-35548986304 10.1038/nn1997
153. Liotta L. A., Tryggvason K., Garbisa S., Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980 284 5751 67 68 2-s2.0-0019195010
154. Bjorklund M., Koivunen E., Gelatinase-mediated migration and invasion of cancer cells. Biochimica et Biophysica Acta 2005 1755 1 37 69 10.1016/j.bbcan.2005.03.001
155. Fingleton B., Matrix metalloproteinases: roles in cancer and metastasis. Frontiers in Bioscience 2006 11 479 491
156. Colotti C., Angeli V., del Ry S., Maltinti M., Vittorini S., Giannessi D., Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: a methodological reappraisal. Clinical Chemistry and Laboratory Medicine 2007 45 10 1292 1298
157. Patel S., Sumitra G., Koner B. C., Saxena A., Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clinical Biochemistry 2011 44 10-11 869 872 2-s2.0-79958782153 10.1016/j.clinbiochem. 2011.04.019
158. Turpeenniemi-Hujanen T., Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005 87 3-4 287 297 2-s2.0-15244348390 10.1016/j.biochi.2005.01.014
159. Liu L., Wu J., Ying Z., Chen B., Han A., Liang Y., Song L., Yuan J., Li J., Li M., Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Research 2010 70 9 3750 3759 2-s2.0-77951725566 10.1158/0008-5472.CAN-09-3838
160. Sbardella D., Fasciglione G. F., Gioia M., Ciaccio C., Tundo G. R., Marini S., Coletta M., Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes. Molecular Aspects of Medicine 2012 33 2 119 208 10.1016/j.mam.2011.10.015
161. Aresu L., Benali S., Garbisa S., Gallo E., Castagnaro M., Matrix metalloproteinases and their role in the renal epithelial mesenchymal transition. Histology and Histopathology 2011 26 3 307 313 2-s2.0-79952350073
162. Ribeiro A. S., Albergaria A., Sousa B., Correia A. L., Bracke M., Seruca R., Schmitt F. C., Paredes J., Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene 2010 29 3 392 402 2-s2.0-75149183984 10.1038/onc.2009.338
163. Levi E., Fridman R., Miao H. Q., Ma Y. S., Yayon A., Vlodavsky I., Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proceedings of the National Academy of Sciences 1996 93 14 7069 7074
164. Gondi C. S., Dinh D. H., Klopffenstein J. D., Gujrati M., Rao J. S., MMP-2 downregulation mediates differential regulation of cell death via ErbB-2 in glioma xenografts. International Journal of Oncology 2009 35 2 257 263 2-s2.0-69449106154 10.3892/ijo-00000335
165. Badiga A. V., Chetty C., Kesanakurti D., Are D., Gujrati M., Klopfenstein J. D., Dinh D. H., Rao J. S., MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS ONE 2011 6 6 2-s2.0-79959187557 10.1371/journal.pone.0020614 e20614
166. Jo Y. K., Park S. J., Shin J. H., Kim Y., Hwang J. J., Cho D. H., Kim J. C., ARP101, a selective MMP-2 inhibitor, induces autophagy-associated cell death in cancer cells. Biochemical and Biophysical Research Communications 2011 404 4 1039 1043 10.1016/j.bbrc.2010.12.106
167. Lampert K., Machein U., Machein M. R., Conca W., Peter H. H., Volk B., Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. American Journal of Pathology 1998 153 2 429 437 2-s2.0-0031855699
168. Yamamoto M., Mohanam S., Sawaya R., Fuller G. N., Seiki M., Sato H., Gokaslan Z. L., Liotta L. A., Nicolson G. L., Rao J. S., Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Research 1996 56 2 384 392
169. Forsyth P. A., Wong H., Laing T. D., Rewcastle N. B., Morris D. G., Muzik H., Leco K. J., Johnston R. N., Brasher P. M., Sutherland G., Edwards D. R., Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. British Journal of Cancer 1999 79 11-12 1828 1835
170. Estève P. O., Chicoine E., Robledo O., Aoudjit F., Descoteaux A., Potworowski E. F., St-Pierre Y., Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. Journal of Biological Chemistry 2002 277 38 35150 35155 10.1074/jbc.M108600200
171. Rao J. S., Yamamoto M., Mohaman S., Gokaslan Z. L., Fuller G. N., Stetler-Stevenson W. G., Rao V. H., Liotta L. A., Nicolson G. L., Sawaya R. E., Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clinical & Experimental Metastasis 1996 14 1 12 18
172. Guo P., Imanishi Y., Cackowski F. C., Jarzynka M. J., Tao H. Q., Nishikawa R., Hirose T., Hu B., Cheng S. Y., Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. The American Journal of Pathology 2005 166 3 877 890
173. Yamada T., Yoshiyama Y., Sato H., Seiki M., Shinagawa A., Takahashi M., White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathologica 1995 90 5 421 424 2-s2.0-0028788221 10.1007/s004010050350
174. Ghosh A., Chaudhuri S., Microglial action in glioma: a boon turns bane. Immunology Letters 2010 131 1 3 9 10.1016/j.imlet.2010.03.003
175. Wisniewski P., Ellert-Miklaszewska A., Kwiatkowska A., Kaminska B., Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NF B-TIMP-2 pathway. Cellular Signalling 2010 22 2 212 220 2-s2.0-70450225051 10.1016/j.cellsig.2009.09.016
176. Baumann F., Leukel P., Doerfelt A., Beier C. P., Dettmer K., Oefner P. J., Kastenberger M., Kreutz M., Nickl-Jockschat T., Bogdahn U., Lactate promotes glioma migration by TGF- β 2-dependent regulation of matrix metalloproteinase-2. Neuro-Oncology 2009 11 4 368 380 10.1215/15228517-2008-106
177. Wick W., Platten M., Weller M., Glioma cell invasion: regulation of metalloproteinase activity by TGF- β Journal of Neuro-Oncology 2001 53 2 177 185 2-s2.0-0034765067 10.1023/A:1012209518843
178. Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A., Oeda E., Tamaki K., Hanai J. I., Heldin C. H., Miyazono K., Ten Dijke P., TGF- β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO Journal 1997 16 17 5353 5362 2-s2.0-0030768644 10.1093/emboj/16.17.5353
179. Imai K., Hiramatsu A., Fukushima D., Pierschbacher M. D., Okada Y., Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor- β 1 release. Biochemical Journal 1997 322 part 3 809 814 2-s2.0-0030958072
180. Yu Q., Stamenkovic I., Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF- β and promotes tumor invasion and angiogenesis. Genes and Development 2000 14 2 163 176 2-s2.0-0034650486
181. Binker M. G., Binker-Cosen A. A., Gaisano H. Y., de Cosen R. H., Cosen-Binker L. I., TGF- β 1 increases invasiveness of SW1990 cells through Rac1/ROS/NF- B/IL-6/MMP-2. Biochemical and Biophysical Research Communications 2011 405 1 140 145 2-s2.0-79551475611 10.1016/j.bbrc.2011.01.023
182. Kim E. S., Sohn Y. W., Moon A., TGF- β -induced transcriptional activation of MMP-2 is mediated by activating transcription factor (ATF)2 in human breast epithelial cells. Cancer Letters 2007 252 1 147 156 2-s2.0-34248401646 10.1016/j.canlet.2006.12.016
183. Dasgupta A., Raychaudhuri B., Haqqi T., Prayson R., van Meir E. G., Vogelbaum M., Haque S. J., Stat3 activation is required for the growth of U87 cell-derived tumours in mice. European Journal of Cancer 2009 45 4 677 684 10.1016/j.ejca.2008.11.027
184. Lo H. W., Cao X., Zhu H., Ali-Osman F., Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to iressa and alkylators. Clinical Cancer Research 2008 14 19 6042 6054 2-s2.0-58149144782 10.1158/1078-0432.CCR- 07-4923
185. Mizoguchi M., Betensky R. A., Batchelor T. T., Bernay D. C., Louis D. N., Nutt C. L., Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. Journal of Neuropathology and Experimental Neurology 2006 65 12 1181 1188 2-s2.0-33845370278 10.1097/01.jnen.0000248549.14962.b2
186. Rahaman S. O., Harbor P. C., Chernova O., Barnett G. H., Vogelbaum M. A., Haque S. J., Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002 21 55 8404 8413 2-s2.0-0037028249 10.1038/sj.onc.1206047
187. Schaefer L. K., Ren Z., Fuller G. N., Schaefer T. S., Constitutive of Stat3 α in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 2002 21 13 2058 2065 2-s2.0-0037150240 10.1038/sj/onc/1205263
188. Chen S. H., Gillespie G. Y., Benveniste E. N., Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases. GLIA 2006 53 2 191 200 2-s2.0-33644804678 10.1002/glia.20264
189. Repovic P., Fears C. Y., Gladson C. L., Benveniste E. N., Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene 2003 22 50 8117 8124 2-s2.0-0344393467 10.1038/sj.onc.1206922
190. Held-Feindt J., Hattermann K., Müerköster S. S., Wedderkopp H., Knerlich-Lukoschus F., Ungefroren H., Mehdorn H. M., Mentlein R., CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Experimental Cell Research 2010 316 9 1553 1566 2-s2.0-77952890503 10.1016/j.yexcr.2010.02.018
191. Yabkowitz R., Meyer S., Black T., Elliott G., Merewether L. A., Yamane H. K., Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 1999 93 6 1969 1979 2-s2.0-0033560025
192. Wang H., Lathia J. D., Wu Q., Wang J., Li Z., Heddleston J. M., Eyler C. E., Elderbroom J., Gallagher J., Schuschu J., MacSwords J., Cao Y., McLendon R. E., Wang X. F., Hjelmeland A. B., Rich J. N., Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009 27 10 2393 2404 2-s2.0-70350223977 10.1002/stem.188
193. Li R., Li G., Deng L., Liu Q., Dai J., Shen J., Zhang J., IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncology Reports 2010 23 6 1553 1559 10.3892/or-00000795
194. Johnston J. B., Silva C., Gonzalez G., Holden J., Warren K. G., Metz L. M., Power C., Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Annals of Neurology 2001 49 5 650 658 2-s2.0-0035004684 10.1002/ana.1007
195. Tsutsui S., Schnermann J., Noorbakhsh F., Henry S., Yong V. W., Winston B. W., Warren K., Power C., A1 Adenosine Receptor Upregulation and Activation Attenuates Neuroinflammation and Demyelination in a Model of Multiple Sclerosis. Journal of Neuroscience 2004 24 6 1521 1529 2-s2.0-1242336753 10.1523/JNEUROSCI.4271-03.2004
196. Beliveau A., Mott J. D., Lo A., Chen E. I., Koller A. A., Yaswen P., Muschler J., Bissell M. J., Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes and Development 2010 24 24 2800 2811 2-s2.0-78650220991 10.1101/gad.1990410
197. Lin C. C., Kuob C. T., Cheng C. Y., Wu C. Y., Lee C. W., Hsieh H. L., Lee I. T., Yang C. M., IL-1 β promotes A549 cell migration via MAPKs/AP-1- and NF- B-dependent matrix metalloproteinase-9 expression. Cellular Signalling 2009 21 11 1652 1662 10.1016/j.cellsig.2009.07.002
198. Coulson-Thomas V. J., Gesteira T. F., Coulson-Thomas Y. M., Vicente C. M., Tersariol I. L. S., Nader H. B., Toma L., Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF- β and extracellular matrix down-regulation. Experimental Cell Research 2010 316 19 3207 3226 2-s2.0-77958153436 10.1016/j.yexcr.2010.08.005
199. Kumar B., Koul S., Petersen J., Khandrika L., Hwa J. S., Meacham R. B., Wilson S., Koul H. K., p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Research 2010 70 2 832 841 10.1158/0008-5472.CAN-09-2918
200. Ehrenfeld P., Conejeros I., Pavicic M. F., Matus C. E., Gonzalez C. B., Quest A. F. G., Bhoola K. D., Poblete M. T., Burgos R. A., Figueroa C. D., Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cells. Cancer Letters 2011 301 1 106 118 2-s2.0-78650558263 10.1016/j.canlet.2010.09.020
201. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R. M., Nishimura S., Imamura Y., Kitayama H., Alexander D. B., Ide C., Horan T. P., Arakawa T., Yoshida H., Nishikawa S., Itoh Y., Seiki M., Itohara S., Takahashi C., Noda M., The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001 107 6 789 800 10.1016/s0092-8674(01)00597-9
202. Coussens L. M., Fingleton B., Matrisian L. M., Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002 295 5564 2387 2392
203. Overall C. M., López-Otín C., Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews Cancer 2002 2 9 657 672